Madrigal Pharmaceuticals

Yahoo Finance • 18 days ago

Is Madrigal Pharmaceuticals (MDGL) The Most Expensive Stock Insiders Are Dumping In March?

We recently published a list of 20 Most Expensive Stocks Insiders Are Dumping In March. In this article, we are going to take a look at where Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) stands against other most expensive stocks insiders... Full story

Yahoo Finance • last month

Madrigal Appoints Jacqualyn A. Fouse, Ph.D. to Its Board of Directors

Fred Craves, Ph.D. to retire from Madrigal’s Board of Directors in July 2025 CONSHOHOCKEN, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel the... Full story

Yahoo Finance • 2 months ago

Madrigal Pharmaceuticals Inc (MDGL) Q4 2024 Earnings Call Highlights: Strong Sales Growth and ...

Net Sales (Q4 2024): $103.3 million, reflecting 66% quarter-over-quarter growth. Net Sales (Full Year 2024): $180.1 million, achieved in nine months of commercialization. Patients on Therapy (End of Q4 2024): Over 11,800 patients actively... Full story

Yahoo Finance • 2 months ago

Madrigal Announces New Two-Year Data from the Compensated MASH Cirrhosis Arm of the MAESTRO-NAFLD-1 Trial Demonstrating Potential Benefit of Rezdiffra™ (resmetirom) in Patients with Compensated MASH Cirrhosis

Patients achieved a mean 6.7 kPa reduction in liver stiffness as measured by vibration-controlled transient elastography (VCTE); this represents the largest reduction in liver stiffness reported in a compensated MASH cirrhosis patient popu... Full story

Yahoo Finance • 2 months ago

Madrigal Pharmaceuticals to Participate in the 45th Annual TD Cowen Health Care Conference

CONSHOHOCKEN, Pa., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the company will participate in the 45th Annual TD Cowen Health Care Conference on Tuesday, March 4, 2025 at 11:10 A.... Full story

Yahoo Finance • 2 months ago

Madrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2024 Financial Results and Host Webcast on February 26, 2025

CONSHOHOCKEN, Pa., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its fourth-quarter and full-year 2024 financial results on Wednesday, Feb. 26, 2025, prior to the ope... Full story

Yahoo Finance • 7 months ago

Is Madrigal Pharmaceuticals, Inc. (MDGL) the Best Guru Stock To Buy Now?

We recently compiled a list of the 10 Best Guru Stocks To Buy Now. In this article, we will have a look at where Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) ranks among the best guru stocks to buy now. Due to the plethora of investment o... Full story

Yahoo Finance • 10 months ago

What's Going On With Fattly Liver Disease Focused Madrigal Pharmaceuticals, Sagimet Biosciences Shares On Wednesday?

What's Going On With Fattly Liver Disease Focused Madrigal Pharmaceuticals, Sagimet Biosciences Shares On Wednesday? On Wednesday, the stocks of Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) and Sagimet Biosciences Inc (NASDAQ:SGMT) are trad... Full story

Yahoo Finance • 12 months ago

Madrigal Pharmaceuticals to Release First-Quarter 2024 Financial Results and Host Webcast on May 7, 2024

Madrigal Pharmaceuticals, Inc. CONSHOHOCKEN, Pa., April 23, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its first-quarter 2024 financial results on Tuesday, May 7, 2024, prio... Full story

Yahoo Finance • last year

15 Best Strong Buy Stocks To Invest In

In this piece, we will take a look at the 15 best strong buy stocks to invest in. If you want to skip our overview of analyst ratings and the finance industry, then you can take a look at the 5 Best Strong Buy Stocks To Invest In. The fin... Full story

Yahoo Finance • last year

3 Stocks That Could Be Monster Winners in 2024

Finding stocks that are huge winners is easy, in retrospect. Doing so before they take off is an entirely different story. However, it's not an impossible task. Three Motley Fool contributors think they've identified stocks that could be... Full story

Yahoo Finance • last year

11 Stocks Insiders and Billionaires Are Crazy About

In this article, we will take a detailed look at the11 Stocks Insiders and Billionaires Are Crazy About. For a quick overview of such stocks, read our article 5 Stocks Insiders and Billionaires Are Crazy About. In his famous book titled O... Full story

Yahoo Finance • last year

Insider Sell Alert: Senior VP Robert Waltermire Sells 3,800 Shares of Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) has recently witnessed a significant insider sell that has caught the attention of investors and market analysts. On December 13, 2023, Senior Vice President and Chief Pharmaceutical Development O... Full story

Yahoo Finance • last year

Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

CONSHOHOCKEN, Pa., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that the c... Full story

Yahoo Finance • last year

11 Best Upside Stocks To Buy Right Now

In this piece, we will take a look at the 11 best upside stocks to buy right now. If you want to skip our overview of share valuation, then take a look at the 5 Best Upside Stocks To Buy Now. The art of buying shares on the market has alw... Full story

Yahoo Finance • last year

Madrigal Pharmaceuticals Appoints Ronald Filippo as Chief Information Officer

CONSHOHOCKEN, Pa., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that Ronal... Full story

Yahoo Finance • last year

Madrigal Pharmaceuticals Presents New Data from the Phase 3 MAESTRO-NASH Trial Demonstrating Broad Treatment Effects of Resmetirom on Noninvasive Measures of Liver Health

Data to be featured in an oral presentation at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting®Analyses from comprehensive set of noninvasive tests used in MAESTRO-NASH provide new insights on strategies to i... Full story

Yahoo Finance • last year

Madrigal Pharmaceuticals Appoints Carole Huntsman as Chief Commercial Officer

CONSHOHOCKEN, Pa., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that Carol... Full story

Yahoo Finance • last year

Madrigal Pharmaceuticals Inc (MDGL) Reports Third Quarter 2023 Financial Results

Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) reported cash, cash equivalents and marketable securities of $232.4 million as of September 30, 2023. Operating expenses for the nine-month period ended September 30, 2023, were $263.3 million, co... Full story

Yahoo Finance • last year

Madrigal Pharmaceuticals Provides Corporate Updates and Reports Third Quarter 2023 Financial Results

Priority Review of resmetirom new drug application underway in the U.S. Bill Sibold appointed Chief Executive Officer of Madrigal in September 2023$500 million financing provides Madrigal with funds to support a potential first-to-market l... Full story